KANK2 and supranuclear palsy, progressive, 1: Nevertheless, we were still able to validate in snRNAseq the bulk RNAseq expression changes in the corresponding nuclei type that led to the discovery of DDR2, KANK2, and STOM as potential therapeutic targets for PSP.